In the Anti-PD1 cohort, derived from breast cancer patients treated with Paclitaxel + Pembrolizumab, high GDF6 expression was found to be associated with treatment resistance (AUC = 0.643, Figure 7F). Here, GDF6 is linked to breast cancer.